Access to NAbs testing important for MS therapy management
Links shared publicly online about this topic.
- 1,234total visits
Access to NAbs testing important for MS therapy management
Teva Neuroscience today announced results at the 62nd American Academy of Neurology Annual Meeting which demonstrated that eliminating barriers to neutralizing antibodies (NAbs) testing significantly impacted multiple sclerosis (MS) treatment choices in patients receiving interferon beta (IFN) therapies.
View full resource at news-medical.net
Tags: Neurology, Multiple Sclerosis, Parkinson's Disease, Disease and Condition, disease, Neuroscience
Most Recently Shared on April 17, 2010 at 1:13 pm By:
Parkinson's Disease: Access to NAbs testing important for MS therapy management: Teva Neuroscience today announced... http://bit.ly/aydXkE
Also Shared By:
Advertisement
News-Medical.Net
@Medicare_News
Medicare News: Access to NAbs testing important for MS therapy management: Teva Neuroscience today announced resul... http://bit.ly/aydXkE
1 year ago...